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Abstract
Background: Extraneural metastases are relatively rare manifestations of medulloblastoma.
Case presentation: We present the case of a young boy with group three MYCN-amplified medulloblastoma. He
received multimodal chemotherapy consisting of gross total resection followed by postoperative craniospinal
radiation and adjuvant chemotherapy. The patient developed extraneural metastases 4 months after the end
of therapy. Literature review identifies the poor prognosis of MYCN-amplified medulloblastomas as well as
extraneural metastases; we review the current limitations and future directions of medulloblastoma treatment options.
Conclusion: To the best of our knowledge, this is the first molecularly characterized report of extraneural metastases of
medulloblastoma in a child.
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Background
Historically, medulloblastoma is the most frequent brain
tumor in children accounting for more than 20% of
pediatric brain tumor cases. Medulloblastoma can
metastasize outside the nervous system and by direct ex-
tension via leptomeningeal seeding. The most common
sites of metastasis are bone and bone marrow, followed by
lymph nodes and, to a lesser extent, liver, lung, and peri-
toneum. Although only 1–2% of medulloblastoma patients
present with extraneural metastasis at the time of initial
diagnosis, the cumulative incidence during follow-up
reaches values of up to 5–10%. To date, 282 patients with
extraneural metastases have been reported. Of these re-
ported cases, 40.4% have occurred in children [1, 2].
Case presentation
A previously healthy 7-year-old boy was hospitalized in
March 2015 with a 1-week history of progressively wors-
ening symptoms of nausea, vomiting and decreased
levels of consciousness. Upon admission, his examin-
ation was significant for diffuse hypotonia (though able
to move all four limbs) and papilledema. A head CT
scan revealed a posterior fossa tumor and obstructive
hydrocephalus [Fig. 1]. An emergent EVD was placed to
relieve the patient’s elevated intracranial pressure. Once
clinically stable, brain and spine MRI was performed and
showed midline posterior fossa tumors and leptomenin-
geal enhancement, suggestive of medulloblastoma with
spine seeding, respectively [Fig. 2]. One week later, he
had a craniotomy with gross total resection of the tumor
on 26/3/2015. Histological diagnosis of the primary
tumor was meduloblastoma, classic subtype.
The case was discussed at our institution’s multidiscip-
linary Neuro-Oncology tumor board. Plans were made
to start multimodal therapy, as per the KFMC high-risk
medulloblastoma protocol. This protocol consists of
6 weeks of craniospinal axis radiotherapy CSI 36 Gy and
a boost to the posterior fossa to a dose of 55.8 Gy/ 31F
concurrently with 2 cycles of oral Etoposide, beginning
day 1 of radiation, oral Etoposide daily for 3 weeks every
4 weeks (i.e., 1 week off ).
Repeat MRI was performed post radiation therapy and
showed post-operative changes and interval improvement
of leptomeningeal enhancement over the spinal cord. Ad-
juvant chemotherapy based on The COG ACNS0332 was
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started on week 11 and consisted of 3 cycles of Cisplatin
and oral Etoposide (cycle A), and 3 cycles of cyclophos-
phamide and Vincristine (cycle B) for a total of 6 alternat-
ing cycles of A and then B, followed by 6 cycles of
maintenance with oral Isotretinoin.
Our patient tolerated chemotherapy very well apart
from one admission for febrile neutropenia following
cycle B chemotherapy; he finished his chemotherapy in
February 2016. Following treatment, the patient was in
good condition, without symptoms suggestive of persist-
ing disease or recurrence. End of therapy follow-up
brain and spine magnetic resonance imaging (MRI)
revealed no signs of recurrence.
However, 2 months after the completion of therapy,
the patient began to complain of a hard and non-
tender right mandibular swelling that gradually in-
creased in size.
Brain and spine MRI was performed and showed no
signs of tumor recurrence in the surgical bed of the pos-
terior fossa and no evidence of CSF seeding metastases
along the spine. However, MRI of the mandibular area
revealed a large necrotic and heterogeneous right
mandibular soft tissue mass with extension into the
infratemporal fossa [Fig. 3].
The patient was re hospitalized in June 2016 for man-
dibular mass incisional biopsy. Histological examination
of the biopsy revealed small, round, blue tumor cells,
consistent with metastasis of medulloblastoma. Immu-
nohistochemistry was performed using commercially
available antibodies according to standard protocols for
paraffin-embedded formalin-fixed tissue. The slides were
incubated with antibodies against GFAP, INI1, synapto-
physin and P53. Histopathology confirmed the diagnosis
of medulloblastoma with classic morphology. No anapla-
sia or excessive nodularity noted in both samples.
Immunohistochemistry for the primary and metastatic
tumors were positive diffusely for synaptophysin and
scattered positive glial staining for GFAP. Staining for
P53 was negative. Intact nuclear staining for INI1, which
confirm the diagnosis of classic medulloblastoma and
rule out atypical teratoid rhabdoid tumor diagnosis.
We used two methods in our molecular testing for the
primary specimen to better classify the genomic sub-
grouping because the next generation sequencing
method alone classified the tumor as either group 3 or
4. The metastatic specimen didn’t have enough materials
for testing.
1. Oncopanel assay
Using a QIAamp DNA FFPE Tissue Kit (Qiagen,
Valencia, CA), we obtained DNA from approximately 5–
10 × 0.6 mm punches containing at least 80% tumor (1 mm
diameter, Miltex, Plainsboro, NJ) from a formalin-fixed
paraffin-embedded (FFPE) tissue block. The concentration
of double-stranded DNA was quantified using a
Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Tech-
nologies, Carlsbad, CA). Next-generation targeted
Fig. 1 Brain MRI revealed a posterior fossa tumor with
obstructive hydrocephalus
Fig. 2 Brain and spine MRI showed a midline posterior fossa tumor suggestive of medulloblastoma with leptomeningeal enhancement concerning
for intraspinal seeding (arrows)
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exon sequencing (Oncopanel) of 300 cancer-related
genes was performed using Illumina-based methods
as previously described [3].
Oncopanel was performed in a CLIA lab and considered
a clinically validated genomics platform for variety of
paediatric brain tumours including the medulloblastoma
sub-classification. Two neuropathologists (MA and SS)
reviewed the tumour specimen and estimated the number
of neoplastic cells in the submitted sample (> 80% viable
tumour cells). Oncopanel assay showed 9,564,899 unique,
aligned, high-quality reads of this specimen, with a mean
of 182 reads across all targeted exons and 98% of all exons
having more than 30 reads. No notable somatic mutations
were detected. Copy number analysis showed MYCN high
amplification red arrow (Fig. 4); ETV1 and SOX9 high
amplification (not shown); monosomies in chromosomes
3, 8, 10, 11, 16 and 21; and polysomy in chromosome 18.
Breakmer analysis identified rearrangements involving (1)
MYCN and a null area (Chr 2:16,086,243–2:18,295,773)
and (2) MYCN and SMC6 (Chr 2:16,086,225–
2:17,847,226). This molecular pattern suggests either
group 3 or 4 medulloblastoma.
2. Methylation assay
Methylation data generated by the Illumina Infinium
HumanMethylation 850 BeadChip array at the molecular
pathology department in NYU. We used the previously
described by the German Cancer Research Center
(DKFZ), in-depth analysis of the DNA methylation [4, 5].
The brain tumor methylation classifier results (v11b2)
reveled methylation class medulloblastoma, subclass
group 3 with calibrated match score to the database of
0.99. The methylation class “medulloblastoma, subclass
group 3” is comprised of tumors with the diagnosis me-
dulloblastoma, genetically defined, group 3. Histologi-
cally most cases fall into the classical (like our case) and
large cell/anaplastic groups. Copy number variation
showed also MYCN amplification (arrow, Fig. 5).
The case was discussed in multidisciplinary Neuro-
Oncology tumor board. Given his diagnosis of extra-
neural metastases, no further medical interventions were
offered. Initially, his general condition was stable, and he
continued palliative care at his home. After a couple of
months, he was admitted again due to a rapid increase
in the size of the mandibular mass. The mass showed
extension into the oral cavity, with erosion and ulcer-
ation of the mucosa. The patient developed feeding diffi-
culties, recurrent massive epistaxis and oral bleeding, he
Fig. 3 MRI of the mandibular area revealed a large necrotic and
heterogeneous right mandibular soft tissue mass with extension
into the infratemporal fossa (arrow)
Fig. 4 Plot of copy number variations by chromosomes that are color-coded. Sex chromosomes are excluded from the analysis. The vertical axis
is the ratio of number of reads for a specimen to a panel of normal samples in log base 2 scales. A value of 0 denotes no difference from normal
(diploid). When the sample contains 100% tumor cells, a value of − 1 is equal to 1 copy loss, and 0.58 is equal to 1 copy gain. The arrow shows
the MYCN amplified region
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required frequent blood product transfusion, including
recombinant factor VIIa, to control bleeding. Unfortu-
nately, with further deterioration of his condition, he
died 18 months after the initial diagnosis.
Discussion and conclusions
Historically despite the heterogeneity of medulloblas-
toma, all patients receive the same therapy. The current
standard of care for children with medulloblastoma
involves maximal surgical resection and adjuvant ther-
apy including both radiotherapy and chemotherapy. Ap-
proximately 80% of children with medulloblastoma are
cured, but current treatment strategies leave medullo-
blastoma survivors with significant long-term morbidity
and debilitating side effects. Frequently, cure of high-risk
patients is difficult to achieve.
Medulloblastoma represent approximately 20% of all
pediatric brain tumors and can be subdivided into 4 dis-
tinct molecular subgroups. These four distinct sub-
groups of medulloblastoma differ in demographics,
somatic genetic events, & clinical outcomes. Current
WHO 2016 classify four distinct subgroups of medullo-
blastoma with distinct demographics, genetics and clin-
ical outcomes. These groups have been designated as
Wnt-positive medulloblastoma, SHH-positive medullo-
blastoma, group 3 and group 4 [1].
Group 4 tumors comprise over 30% of all medulloblas-
toma and occur mainly in older children, though they can
occur in adults and similar to group 3, more frequently
occur in males. Group 4 medulloblastoma have a similar
prognosis to SHH-positive tumors most groups 4 medul-
loblastoma have a classic histology. Group 3. Histologi-
cally most cases fall into the classical and large cell/
anaplastic groups. Tumors are located in the cerebellum,
typically in the vermis. Median age is 4 years (range 1 to
17). Group 3 medulloblastomas are more common in
males than females. MYC amplification, aneuploidy, iso-
chromosome 17q and GFI1/1B activation by enhancer
hijacking are recurrent features, but a fraction lack an ob-
vious driving genetic change [3–6].
Medulloblastoma metastases usually occur along the
route of the cerebrospinal flow (i.e., the ventricular
system and spinal cord). The extraneural metastases of
primary brain tumors are relatively rare, accounting for
5–10% of all medulloblastoma cases.
Mechanisms of extraneural spread of medulloblastoma
are still unclear. Craniotomy and surgical interventions
mechanically disrupt the blood-brain barrier and allow
migration of the tumor cells. Both hematogenic and
lymphatic (involving cervical and retro auricular lymph
nodes) spread of primary brain tumor cells have been sug-
gested [7, 8]. Another frequently suggested mechanism for
the extraneural spread of medulloblastoma is iatrogenic
dissemination via ventriculoperitoneal shunts, which is
likely to lead primarily to peritoneal metastases [8].
The majority of extraneural metastases of Medullo-
blastoma occur relatively early after initial diagnosis.
While leptomeningeal and posterior fossa metastases are
Fig. 5 Methylation analysis for copy numbers analysis. Depiction of chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/
amplifications represent positive, losses negative deviations from the baseline. 29 brain tumor relevant gene regions are highlighted for
easier assessment. Arrow highlights MYCN amplification
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diagnosed in the first 5 years in 80–85% of the pediatric
cases, nearly 80% of the extraneural metastases are discov-
ered within the first 3 years after initial diagnosis [7, 8].
Concurrent central nervous system involvement, pul-
monary or liver metastasis, early development of extra-
neural metastasis (< 18 months after initial diagnosis), and
patient age of < 16 years at the time of extraneural metas-
tasis diagnosis are all associated with poorer prognosis [8].
Recurrence patterns across medulloblastoma sub-
groups have been described, and it was found that me-
dulloblastoma does not typically change subgroup at the
time of recurrence, further highlighting the stability of
the four-principle medulloblastoma subgroups [6, 8, 9].
Additionally, significant differences in the location and
timing of recurrence across medulloblastoma subgroups
were observed which have potential treatment ramifica-
tions. Specifically; SHH-positive tumors recur mostly in
the local tumor bed, while group 3 and group 4 tumors
recur mostly with extraneural metastases and do not re-
lapse in the primary site, Group 4 tumors also have an
increased time to death following recurrence.
These findings suggest that microscopic leptomenin-
geal metastases in group 3 and group 4 tumors not vis-
ible by neuroimaging or CSF examination are likely to
be resistant to current therapy. Thus, additional local
therapies targeting the primary site in the posterior fossa
are unlikely to increase the cure rate for patients with
group 3 or group 4 medulloblastoma, further reinforcing
the importance of generating novel approaches to ther-
apy in the metastatic compartment [8, 9].
The identification of molecular subgroups of medullo-
blastoma has potential to aid in understanding when it
is possible to reduce standard chemotherapy doses and/
or radiation therapies for children with favorable mo-
lecular medulloblastoma subgroups. Also intensify the
therapy and /or use of maintenance-targeted therapies
for high-risk medulloblastoma [10].
Recent study used highly integrative genomic analysis
of medulloblastoma from 579 medulloblastoma samples,
which led to identification of new subgroup-specific
driver genes, epigenetic subtypes, and candidate targets
for therapy [3].
The epigenetic defining group 3 and Group 4 MB sub-
groups are not as clearly demarcated as their WNT and
SHH counterparts. This molecular heterogeneity could
further help in predicting different clinical behavior in
groups 3 and 4 and design better-targeted therapy. How-
ever, more clinical validation to this study is needed [3].
C-MYC (MYC), oncogene as well as its paralogs
MYCN and MYCL1, has been shown to play essential
roles in cycling progenitor cells born from proliferating
zones during embryonic development. After birth, MYC
plays important roles in the proliferation of all cell types.
MYC, MYCN, and MYCL1 amplifications have all been
described in medulloblastomas and associated with poor
prognosis [11–13].
Ongoing St. Jude MB protocol study (SJMB12) inten-
sify therapy for stratum N3 High Risk patients with
MYC/MYCN amplification who will receive high dose
craniospinal radiation with boost to the primary tumor
and standard chemotherapy (cisplatin, vincristine, cyclo-
phosphamide) for 4 cycles intermixed with an additional
3 cycles of chemotherapy with pemetrexed and gemcita-
bine (https://clinicaltrials.gov/show/NCT01878617).
Novel agents are being tested as potential therapeutics
for medulloblastoma. These agents include drugs that
suppress expression of MYC isoforms by inhibiting bro-
modomain containing 4 (BRD4), a bromodomain. The
preclinical evaluation of BET bromodomain inhibitors in
MYCN-amplified medulloblastoma is also ongoing [14].
In summary, routine molecular profiling of medullo-
blastoma may give oncologists a more thorough under-
standing of tumors of unfavorable molecular subgroups
that are at increased risk of extraneural metastases. This
approach may help modify therapeutic approaches for
children with unfavorable medulloblastoma molecular
subgroups and have real implications for precision medi-
cine in our oncology practice.
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